Safe anticoagulation for patients with CKD—are we there yet?

被引：0
|
作者：
Elsayed Z. Soliman
机构：
[1] Epidemiological Cardiology Research Center (EPICARE),
[2] Wake Forest School of Medicine,undefined
[3] Medical Center Boulevard,undefined
来源：
Nature Reviews Nephrology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Data from the ARISTOTLE trial showed that apixaban, compared with warfarin, reduced the rates of stroke, death and major bleeding in patients with atrial fibrillation, regardless of renal function. Is the problem of balancing the risks of thromboembolism and bleeding in patients with atrial fibrillation and chronic kidney disease finally solved?
引用
收藏
页码：689 / 690
页数：1
相关论文
共 50 条
  • [11] Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
    Benjamin Cross
    Richard M. Turner
    J. Eunice Zhang
    Munir Pirmohamed
    The Pharmacogenomics Journal, 2024, 24
  • [12] Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
    Cross, Benjamin
    Turner, Richard M.
    Zhang, J. Eunice
    Pirmohamed, Munir
    PHARMACOGENOMICS JOURNAL, 2024, 24 (02):
  • [13] Anticoagulation in CKD and ESRD
    Leung, Kelvin Cheuk-Wai
    MacRae, Jennifer Marie
    JOURNAL OF NEPHROLOGY, 2019, 32 (05) : 719 - 731
  • [14] Anticoagulation in CKD and ESRD
    Kelvin Cheuk-Wai Leung
    Jennifer Marie MacRae
    Journal of Nephrology, 2019, 32 : 719 - 731
  • [15] GOLDEN PILL - WE CANT YET BE SURE ITS SAFE
    MINTZ, M
    NEW REPUBLIC, 1968, 158 (09) : 18 - 20
  • [16] Are we not there yet? Who can keep the Pandora box safe?
    Moon, Ho Sik
    Chon, Jin Young
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2013, 30 (01) : 38 - 39
  • [17] Are we there yet? Are we there yet?
    Conrad, Charles
    Malphurs, Ryan
    MANAGEMENT COMMUNICATION QUARTERLY, 2008, 22 (01) : 123 - 146
  • [18] SAFE CELL AND GENE THERAPY COMBINATION: ARE WE THERE YET IN ARTHRITIS?
    Nagy, A.
    Neely, E. J.
    OSTEOARTHRITIS AND CARTILAGE, 2019, 27 : S16 - S16
  • [19] Anticoagulation in Patients With Stroke With Infective Endocarditis Is Safe
    Rasmussen, Rasmus Vedby
    STROKE, 2011, 42 (06) : 1795 - 1796
  • [20] RIVAROXABAN VS WARFARIN AS ORAL ANTICOAGULATION THERAPY IN CKD PATIENTS
    Di Lullo, Luca
    Ronco, Claudio
    De Pascalis, Antonio
    Granata, Antonio
    Cozzolino, Mario
    Russo, Domenico
    Di Iorio, Biagio
    Barbera, Vincenzo
    Bellasi, Antonio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
12345